16 August 2017
Visiongain’s new report Biosimulation World Market 2017-2027: Revenue Prospects by Product (PK/PD, Molecular, Toxicity, PBPK, Trial Design), Services (In-House, External), Application (Drug Development, Preclinical Testing, ADME/Tox, PK/PD, Clinical Trials, Drug Discovery, End User (Pharmaceutical and Biotechnology Companies, CROs, Academic & Government, Regulatory Authorities) and Geography indicates that the global biosimulation market will see over $1.2bn in revenue in 2017.
The lead analyst of the report said:
“Biosimulation is computer-aided mathematical simulation of biological processes to build a systematic approach for integrating clinical data into functional metabolic pathways. Biosimulation is widely adopted in the areas of drug discovery and development and is a vital decision-making tool for predictive studies.
The market is mainly driven by growth in R&D investments made by the biotechnology and pharmaceutical industries. Other factors that are expected to drive the market include technological advancements such as quantitative systems pharmacology (QSP), the need to reduce drug discovery and development costs, and high growth in biologics and biosimilars, along with the increased use of personalized medicines. The emerging applications of biosimulation in other industries will provide new growth opportunities to players in the biosimulation market.
There has been high adoption of biosimulation in the recent few years due to which the competitive landscape has intensified in competition, however certain factors such as lack of standardization and lack of trained professionals can pose as a hurdle to the growth of the biosimulation market. Although, these restraints can pose as an obstacle to market growth, trends such as collaborations of universities and research labs with suppliers are expected to create major opportunities for the manufactures of biosimulation software, thereby driving market growth.”
The 148-page report contains 112 tables, charts and graphs that add visual analysis in order to explain developing trends within the Biosimulation market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading Biosimulation software submarkets, segmented by product, including forecasts for PK/PD, Molecular, Toxicity, PBPK, Trial Design. The market is also segmented by application, with forecasts for Drug Development, Preclinical Testing, ADME/Tox, PK/PD, Clinical Trials and Drug Discovery from 2017-2027. In addition, the biosimulation market is segmented by end-user, with forecasts for Pharmaceutical and Biotechnology Companies, CROs, Academic & Government, Regulatory Authorities. There are also forecasts for the Biosimulation Services market, with forecasts for In-House and external/contract services.
The 148-page report offers market forecasts and analysis for 11 key national markets. In addition, the report contains a dedicated leading companies’ chapter covering 10 companies leading the Biosimulation field in detail.
The Biosimulation World Market 2017-2027: Revenue Prospects by Product (PK/PD, Molecular, Toxicity, PBPK, Trial Design), Services (In-House, External), Application (Drug Development, Preclinical Testing, ADME/Tox, PK/PD, Clinical Trials, Drug Discovery, End User (Pharmaceutical and Biotechnology Companies, CROs, Academic & Government, Regulatory Authorities) and Geography report will be of value to anyone who wants to better understand the Biosimulation market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the biosimulation industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market